Takeda Files Q3 2023 Quarterly Securities Report in English
Ticker: TKPHF · Form: 6-K · Filed: Feb 2, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Feb 2, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: quarterly-report, financial-disclosure, regulatory-filing
TL;DR
**Takeda just dropped its Q3 2023 financial report, giving us a look at their performance through December.**
AI Summary
Takeda Pharmaceutical Company Limited filed a 6-K report on February 2, 2024, to announce the submission of its Quarterly Securities Report for the nine-month period ended December 31, 2023, to the Kanto Local Finance Bureau in Japan. This filing provides investors with an English translation of the detailed financial performance and operational updates for the past three quarters, which is crucial for understanding the company's health and future prospects.
Why It Matters
This filing provides transparency into Takeda's financial performance for the nine months ending December 31, 2023, allowing investors to assess its operational health and make informed decisions.
Risk Assessment
Risk Level: low — This 6-K filing is a routine disclosure of a quarterly report, which is standard for public companies and does not inherently introduce new risks.
Analyst Insight
Investors should review the full English translation of the Quarterly Securities Report for the nine-month period ended December 31, 2023, to gain a comprehensive understanding of Takeda's financial performance and operational developments.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — the registrant filing the 6-K
- Kanto Local Finance Bureau (organization) — Japanese regulatory body where the report was filed
- February 2, 2024 (date) — date of the 6-K filing and the Quarterly Securities Report submission
- December 31, 2023 (date) — end date of the nine-month period covered by the report
FAQ
What is the primary purpose of Takeda Pharmaceutical Company Limited's 6-K filing on February 2, 2024?
The primary purpose of Takeda Pharmaceutical Company Limited's 6-K filing on February 2, 2024, is to furnish an English translation of its Quarterly Securities Report for the nine-month period ended December 31, 2023, which was previously filed with the Director of the Kanto Local Finance Bureau in Japan.
Which regulatory body in Japan received Takeda's Quarterly Securities Report?
Takeda's Quarterly Securities Report for the nine-month period ended December 31, 2023, was filed with the Director of the Kanto Local Finance Bureau in Japan.
What period does the Quarterly Securities Report, included as an exhibit, cover?
The Quarterly Securities Report included as an exhibit covers the nine-month period and three-month quarter ended December 31, 2023.
What is Takeda Pharmaceutical Company Limited's Commission File Number with the SEC?
Takeda Pharmaceutical Company Limited's Commission File Number with the SEC is 001-38757.
Was the Financial Appendix included directly in this 6-K filing?
No, the Financial Appendix (Exhibit 99.1) was incorporated by reference to Exhibit 99.1 to a Form 6-K of the Registrant, filed on February 1, 2024, not directly included in this specific February 2, 2024 filing.
Filing Stats: 4,593 words · 18 min read · ~15 pages · Grade level 7.4 · Accepted 2024-02-02 06:16:40
Filing Documents
- form6k_020224.htm (6-K) — 1101KB
- 0001395064-24-000016.txt ( ) — 1102KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date February 2, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller Table of Contents Translation for reference purpose only Quarterly Securities Report (The third quarter of 147th Business Term) for The Nine-month Period and Three-month Quarter Ended December 31, 2023 TAKEDA PHARMACEUTICAL COMPANY LIMITED AND ITS SUBSIDIARIES Table of Contents Translation for reference purpose only Index Page Cover 1 A. Company Information I. Overview of Takeda 2 1. Key Consolidated Financial Data 2 2. Business Overview 2 II. Operating and Financial Review 3 1. Risk Factors 3 2. Analysis on Business Performance, Financial Position and Cash Flows 3 3. Material Contracts 18 III. Information on the Company 19 1. Information on the Company's Shares 19 2. Members of the Board of Directors 20 IV. Financial Information 21 1. Condensed Interim Consolidated Financial Statements 22 2. Others 42 B. Information on Guarantors of the Company 43 Table of Contents Translation for reference purpose only Cover Document Filed Quarterly Securities Report Applicable Law Article 24-4-7, paragraph 1 of the Financial Instruments and Exchange Act of Japan Filed with Director, Kanto Local Finance Bureau Filing Date February 2, 2024 Fiscal period The third quarter of 147th Business Term (from October 1, 2023 to December 31, 2023) Company Name Takeda Pharmaceutical Company Limited Title and Name of Representative Christophe Weber, Representative Director, President Chief Executive Officer Address of Head Office 1-1, Doshomachi 4-chome, Chuo-ku, Osaka (The above address is the registered head office location and the ordinary business operations are conduc